Enzyme inhibition as a potential therapeutic strategy to treat COVID-19 infection
| Autor: | Andrew K. Snabaitis, Lukas Paulsson-Habegger, Stephen P. Wren |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Coronavirus disease 2019 (COVID-19)
viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clinical Biochemistry Pharmaceutical Science Virulence ACE2 Review Article Spike protein medicine.disease_cause chemistry Biochemistry Antiviral Agents Virus Angiotensin Receptor Antagonists RAAS Viral entry Drug Discovery medicine Animals Humans Janus Kinase Inhibitors Molecular Biology Furin TMPRSS2 Coronavirus Therapeutic strategy ComputingMethodologies_COMPUTERGRAPHICS Inhibition Receptors Angiotensin biology Chemistry SARS-CoV-2 Organic Chemistry COVID-19 Virology infection COVID-19 Drug Treatment Enzymes Drug Combinations Methotrexate biology.protein Molecular Medicine Angiotensin-Converting Enzyme 2 biological Signal Transduction |
| Zdroj: | Bioorganic & Medicinal Chemistry |
| ISSN: | 0968-0896 |
| Popis: | Graphical abstract With the emergence of the third infectious and virulent coronavirus within the past two decades, it has become increasingly important to understand how the virus causes infection. This will inform therapeutic strategies that target vulnerabilities in the vital processes through which the virus enters cells. This review identifies enzymes responsible for SARS-CoV-2 viral entry into cells (ACE2, Furin, TMPRSS2) and discuss compounds proposed to inhibit viral entry with the end goal of treating COVID-19 infection. We argue that TMPRSS2 inhibitors show the most promise in potentially treating COVID-19, in addition to being a pre-existing medication with fewer predicted side-effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect